Henry Schein (HSIC) experienced a series of notable activities, including analyst downgrades, partnership developments, and financial performance.
CFRA downgraded HSIC to
Sell, also reducing the target price. HSIC entered an agreement with Biomerica for marketing the latter's inFoods® IBS Test in the U.S. However, their stock has been
underperforming the healthcare sector causing concern. The company's
valuation is under scrutiny, particularly as the
U.S. Dental demand weakens potentially affecting the company's growth. The Q2 earnings were aligned with market expectations, though the
stock price declined. There's been an expansion in SolutionsHub, additionally increasing their buyback capacity to US$750 Million. HSIC also announced a
$400 Million increase to share repurchase plan. Analysts argue the market has low tolerance for company's mixed fundamentals. The investment by KKR and board changes provided some direction for the company with preliminary unaudited results and 2025 financial guidance being released. On a positive note, Henry Schein MEDICAL expanded SolutionsHub. Yet, the Q1 earnings were missed by 24%, causing most to revise their forecasts. However, the stock remains a
top-ranked value stock.
Henry Schein HSIC News Analytics from Fri, 17 Jan 2025 08:00:00 GMT to Sat, 18 Oct 2025 08:39:25 GMT -
Rating -1
- Innovation 4
- Information 8
- Rumor 0
